Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
You may also be interested in...
Gilead’s authorized generics for Epclusa and Harvoni will be first alternatives to benefit from preferred coverage on the pharmacy benefit manager's National Preferred Flex Formulary.
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
Two-and-a-half years after receiving a complete response letter, Teva's ANDA clears FDA; agency issued three guidances for development of generic epinephrine auto-injectors.